Universal reference book for medicines

Active substance: aminophenylbutyric acid

Type: Nootropic drug with anxiolytic activity

Composition, form of production and packaging
Tablets from white to white with a slightly yellowish hue of color, round, flat-cylindrical, spastic and risky.
1 tab.

aminophenylbutyric acid hydrochloride 250 mg

Excipients: lactose - 180 mg, potato starch - 65 mg, calcium stearate - 5 mg.

10 pieces.
- packings cellular planimetric (2) - packs cardboard.

Description of the drug approved by the manufacturer for the printed edition of 2016.


Phenibut normalizes metabolic processes in the nerve cells of the brain.
The active substance of the preparation Phenibut (aminophenylbutyric acid hydrochloride) can be considered as a derivative of y-amino-butyric acid (GABA) or as a derivative of? -phenylethylamine. Phenibut has nootropic activity, and as a derivative of GABA has an anxiolytic (tranquilizing) effect. Does not affect cholino- and adrenergic receptors.
The drug reduces tension, anxiety, fear and improves sleep, so it is used to treat neuroses and before surgery.
Phenibut prolongs and intensifies the effect of hypnotics, narcotic, neuroleptic and anti-Parkinsonian drugs. Phenibut is devoid of anticonvulsant activity. Phenibut extends the latent period. nystagmus and shortens its duration and severity. The drug reduces the manifestations of asthenia and vasovegetative symptoms, incl. headache, a feeling of heaviness in the head, sleep disturbances, irritability, emotional lability and increases mental performance. Psychological indicators (attention, memory, speed and accuracy of sensory-motor reactions) under the influence of the drug Fenibut are improved, in contrast to the influence of tranquilizers. In patients with asthenia and emotionally labile patients, from the first days of therapy, subjective well-being improves, interest and initiative, motivation of activity increases.

Aminophenylbutyric acid is well absorbed after ingestion and penetrates into all tissues of the body, easily overcomes the blood-brain barrier.
In the brain tissue penetrates about 0.1% of the administered dose of the drug, and in young and old people to a much greater extent. Metabolised in the liver - 80-95%, to pharmacologically inactive metabolites. About 5% is excreted by the kidneys unchanged, in part - with bile. At repeated reception cumulation is not observed.

- asthenic and anxiety-neurotic states;

stammering, tics and enuresis in children;

- Insomnia and nightly anxiety in the elderly;

- Meniere's disease,

- dizziness associated with dysfunction of the vestibular analyzer of various genesis;

- prevention of motion sickness with kinetosis;

- as part of complex therapy for alcohol withdrawal syndrome for relief of psychopathological and somatovegetative disorders.


Take inside after eating.

Tablets can be divided.

Asthenic and anxiety-neurotic states

Adults : 250-500 mg 3 times / day.
The maximum single dose is 750 mg (3 tablets), for patients over 60 years - 500 mg. The course of treatment is 2-3 weeks. If necessary, the course of treatment can be extended to 4-6 weeks.
Children: from 3 to 8 years -125 mg to 3 times / day;
from 8 to 14 years - 250 mg 3 times / day; children over 14 years of age - doses for adults.
Stammering, tics and enuresis in children: from 3 to 8 years -125 mg to 3 times / day;
from 8 to 14 years - 250 mg 3 times / day; children over 14 years of age - doses for adults.
Insomnia and night anxiety in the elderly: 250-500 mg 3 times / day.

Ménière's disease, dizziness associated with dysfunction of the vestibular analyzer of various origins

During the exacerbation in adults 750 mg 3-4 times / day for 5-7 days, then 250-500 mg 3 times / day for 5-7 days and then 250 mg 1 time / day for 5 days.
For treatment of dizziness with dysfunctions of the vestibular analyzer of vascular and traumatic genesis - 250 mg 3 times / day for 12 days.
Prevention of motion sickness with kinetosis: 250-500 mg once for 1 hour before the proposed journey or when the first symptoms of motion sickness appear.

The anti-sweating action is enhanced by increasing the dose of the drug.
The drug is ineffective in the manifestations of motion sickness ("indomitable" vomiting and others).
As part of complex therapy for alcohol withdrawal syndrome for the relief of psychopathological and somatovegetative disorders at the beginning of treatment in the daytime 250-500 mg 3 times / day and at night 750 mg, with a gradual decrease in the daily dose to normal for adults.


Phenibut, like other drugs, can cause side effects, which are not apparent in all patients.
Usually, Phenibut is usually well tolerated. Possible:
From the nervous system: drowsiness and increased symptoms (at the beginning of treatment), dizziness, headache.

From the gastrointestinal tract: nausea (at the beginning of treatment).

From the skin and subcutaneous tissues: allergic reactions (skin rash, itching).

From the liver and biliary tract: with prolonged use of high doses - hepatotoxicity.


- hypersensitivity to the active substance or excipients of the drug;

- Pregnancy;

- breast-feeding;

- children under 3 years;

- the preparation contains lactose.
Do not use in patients with a rare congenital intolerance to galactose, a deficiency of lactase, or glucose-galactose malabsorption.

Patients with erosive and ulcerative gastrointestinal diseases because of the irritant effect of the drug is recommended to prescribe smaller doses of the drug.


Use during pregnancy and during lactation is not recommended, because
there is not enough clinical observation.
In experimental animal studies, a mutagenic, teratogenic and embryotoxic action of the drug has not been established.


Contraindicated use of the drug for children under the age of 3 years.

At asthenic and anxious-neurotic states: children - from 3 to 8 years -125 mg to 3 times / day;
from 8 to 14 years - 250 mg 3 times / day; children over 14 years of age - doses for adults.
Stammering, tics and enuresis in children: children from 3 to 8 years -125 mg to 3 times / day;
from 8 to 14 years - 250 mg 3 times / day; children over 14 years of age - doses for adults.

With prolonged use (more than 2-3 weeks), it is necessary to monitor the parameters of peripheral blood and liver function every 2-3 weeks.

Influence on ability to drive vehicles or service potentially dangerous mechanisms

During the treatment period, care must be taken when driving vehicles and engaging in other potentially hazardous activities requiring increased attention and speed of psychomotor reactions, since some patients may experience CNS disorders such as drowsiness and dizziness.


The drug is low toxic.
Data on cases of overdose was not felt.
Symptoms: drowsiness, nausea, vomiting, dizziness.
With prolonged use of high doses, eosinophilia, a decrease in blood pressure, a violation of renal activity, fatty degeneration of the liver (reception more than 7 g) can develop.
Treatment: gastric lavage, symptomatic treatment, maintenance of vital functions.
There is no specific antidote.

For the purposes of mutual potentiation, aminophenylbutyric acid can be combined with other psychotropic drugs, reducing the dose of aminophenylbutyric acid and the combined medicines.

Extends and enhances the effect of hypnotics, neuroleptic, anticonvulsant and antiparkinsonian drugs.


The drug is released by prescription.


The drug should be stored in a dry, protected from light and out of reach of children at a temperature of no higher than 25 ° C.
Shelf life - 3 years.
Do not use the drug after the expiry date printed on the package.

Alphabetical index of medicines:
A  B  V  G  D  E  J
Z  I  Y  K  L  M  N
O  P  R  S  T  U  F
H  C  CH  SH  E  U  Y
Privacy policy:
Copyright 2009 - 2017. Universal reference book of medicines. All rights reserved.
When using site materials, an active hyperlink is required!